Ayush B. Rana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayush B. Rana has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Scott M. Welford
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.
2 shared publications Alejandro V Villarino
Department of Microbiology and Immunology, Miller School of Medicine, University of Miami , Miami, Florida
1 shared publicationAshish H Shah
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , Miami, Florida
1 shared publication- Barbara Bedogni
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine University of Miami Miami Florida USA
1 shared publication David B Lombard
Bruce W. Carter VAMC , Miami, Florida
1 shared publicationDazhi Wang
Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine , Miami, Florida
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Polyamines in CNS malignancies: positively charged culprits in the hijacking of neural and immune signaling pathways
The mammalian polyamines (putrescine, spermidine and spermine) are ubiquitous polycations, long recognized for their indispensable roles in maintaining cell proliferation, differentiation and survival. Traditionally viewed as metabolic supporters of growth, polyamines have recently emerged as active regulators of cell-cell signaling in diverse physiological and pathological settings. Through intercellular polyamine transfer, modulation of ion channels and interactions with cell-surface receptors, polyamines orchestrate intricate signaling networks, from neurotransmission in the nervous system to cytokine signaling in the immune compartment. Many cancers, though most clearly, central nervous systems (CNS) cancers, exploit neuro- and immunomodulatory circuits, effectively hijacking neural and immune signaling pathways to sustain growth and evade surveillance. Thus, an integrated, multi-disciplinary perspective is required to overcome hurdles in the treatment of these aggressive malignancies. In light of ongoing clinical trials aimed at disrupting polyamine synthesis and transport in brain tumors, better defining the role of polyamines in mediating tumor-host interactions is essential for maximizing anti-tumor efficacy while minimizing normal tissue toxicity. This review integrates advances from cancer biology, immunology and neuroscience to comprehensively discuss the mechanisms through which polyamines regulate cell-cell signaling, the role of these pathways in brain tumor progression and the diagnostic and therapeutic opportunities that arise from this knowledge.
- 4 July 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Open AccessPolyamines in CNS malignancies: positively charged culprits in the hijacking of neural and immune signaling pathways
The mammalian polyamines (putrescine, spermidine and spermine) are ubiquitous polycations, long recognized for their indispensable roles in maintaining cell proliferation, differentiation and survival. Traditionally viewed as metabolic supporters of growth, polyamines have recently emerged as active regulators of cell-cell signaling in diverse physiological and pathological settings. Through intercellular polyamine transfer, modulation of ion channels and interactions with cell-surface receptors, polyamines orchestrate intricate signaling networks, from neurotransmission in the nervous system to cytokine signaling in the immune compartment. Many cancers, though most clearly, central nervous systems (CNS) cancers, exploit neuro- and immunomodulatory circuits, effectively hijacking neural and immune signaling pathways to sustain growth and evade surveillance. Thus, an integrated, multi-disciplinary perspective is required to overcome hurdles in the treatment of these aggressive malignancies. In light of ongoing clinical trials aimed at disrupting polyamine synthesis and transport in brain tumors, better defining the role of polyamines in mediating tumor-host interactions is essential for maximizing anti-tumor efficacy while minimizing normal tissue toxicity. This review integrates advances from cancer biology, immunology and neuroscience to comprehensively discuss the mechanisms through which polyamines regulate cell-cell signaling, the role of these pathways in brain tumor progression and the diagnostic and therapeutic opportunities that arise from this knowledge.
- 27 May 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (10) , 2574-2591
Polyamine acetylation mediates crosstalk between cancer cells and myeloid cells to promote mesenchymal/plurimetabolic states in glioblastoma
Background: Metabolic reprogramming in glioblastoma (GBM) is a putative determinant of GBM subtype, malignant cell state, and tumor-immune crosstalk. In the present study, we investigated how polyamine metabolic rewiring contributes to the malignant cell-intrinsic and microenvironment-dependent biological processes underpinning GBM subtype classification. Methods: Liquid chromatography/tandem mass spectrometry was used for polyamine quantification in human and murine GBM tumors and cell lines. Through single-cell RNA sequencing, metabolic profiling, and additional functional experiments, we dissect the malignant cell-intrinsic and paracrine signaling processes regulated by SAT1 (spermidine/spermine-N1-acetyltransferase1) and its product, N1-acetylspermidine. Results: We find that polyamine acetylation is elevated in human and murine GBM tumors and contributes to the classification of mesenchymal/plurimetabolic GBM through both regulation of tumor-cell intrinsic glucose metabolism and by facilitating metabolic crosstalk with tumor-associated macrophages/myeloid cells (TAMs). The impact of SAT1 on tumor cell metabolism is mediated, at least in part, by N1-acetylspermdine, the sole polyamine elevated in human and murine tumors. Furthermore, the relatively high levels of N1-acetylspermidine released by GBM are taken up by myeloid cells to promote intracellular polyamine flux, cellular respiration, and migration. In vivo, both genetic disruption of polyamine acetylation and pharmacological inhibition of polyamine transport reduced myeloid cell infiltration and sensitized tumors to chemoradiation. Conclusions: Collectively, the findings highlight a previously unidentified role for SAT1 and its product, N1-acetylspermidine, in bridging the metabolic activity of tumor cells and TAMs, together promoting mesenchymal/plurimetabolic states and therapeutic resistance in GBM.
- 27 May 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (10) , 2574-2591
Polyamine acetylation mediates crosstalk between cancer cells and myeloid cells to promote mesenchymal/plurimetabolic states in glioblastoma
Background: Metabolic reprogramming in glioblastoma (GBM) is a putative determinant of GBM subtype, malignant cell state, and tumor-immune crosstalk. In the present study, we investigated how polyamine metabolic rewiring contributes to the malignant cell-intrinsic and microenvironment-dependent biological processes underpinning GBM subtype classification. Methods: Liquid chromatography/tandem mass spectrometry was used for polyamine quantification in human and murine GBM tumors and cell lines. Through single-cell RNA sequencing, metabolic profiling, and additional functional experiments, we dissect the malignant cell-intrinsic and paracrine signaling processes regulated by SAT1 (spermidine/spermine-N1-acetyltransferase1) and its product, N1-acetylspermidine. Results: We find that polyamine acetylation is elevated in human and murine GBM tumors and contributes to the classification of mesenchymal/plurimetabolic GBM through both regulation of tumor-cell intrinsic glucose metabolism and by facilitating metabolic crosstalk with tumor-associated macrophages/myeloid cells (TAMs). The impact of SAT1 on tumor cell metabolism is mediated, at least in part, by N1-acetylspermdine, the sole polyamine elevated in human and murine tumors. Furthermore, the relatively high levels of N1-acetylspermidine released by GBM are taken up by myeloid cells to promote intracellular polyamine flux, cellular respiration, and migration. In vivo, both genetic disruption of polyamine acetylation and pharmacological inhibition of polyamine transport reduced myeloid cell infiltration and sensitized tumors to chemoradiation. Conclusions: Collectively, the findings highlight a previously unidentified role for SAT1 and its product, N1-acetylspermidine, in bridging the metabolic activity of tumor cells and TAMs, together promoting mesenchymal/plurimetabolic states and therapeutic resistance in GBM.